About
Technology
Issues
FAQ
Links
Official Page
Characterization of complete responses (CRs) in patients with advanced melanoma (MEL) who received the combination of nivolumab (NIVO) and ipilimumab (IPI), NIVO or IPI alone
Distribution of the number of citations over years.
site/software ©
exaly
; All materials licenced under
CC by-SA
.